The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: Recent challenges and their implications for the novel drug development
Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: recent challenges and their implications for the novel drug development. J Pharmacol Exp Ther 2003 306 : 821 827.
The k variant of butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients
Ballard C, Morris C, Kalaria R et al. The k variant of butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord 2005 19 : 357 360.
Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans
Reiter RJ, Tan D-X, Mayo JC et al. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003 50 : 1129 1146.
Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species
Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines
Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009 47 : 109 126.
A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation
Tan D, Manchester LC, Reiter RJ et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998 253 : 614 620.
The synthesis and the structure elucidation of N,O-diacetyl derivative of cyclic 3-hydroxymelatonin
Siwicka A, Reiter RJ, Tian D-X et al. The synthesis and the structure elucidation of N,O-diacetyl derivative of cyclic 3-hydroxymelatonin. Cent Eur J Chem 2004 2 : 425 433.
The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity
Siwicka A, Molȩda Z, Wojtasiewicz K et al. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity. J Pineal Res 2008 45 : 40 49.
Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia
Di Fabio R, Conti N, De Magistris E et al. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. J Med Chem 1999 42 : 3486 3493.
Structural determinants of Torpedo californica acetylcholinesterase inhibitors by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819)
Bartolucci C, Siotto M, Ghidini E et al. Structural determinants of Torpedo californica acetylcholinesterase inhibitors by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819). J Med Chem 2006 49 : 5051 5058.
Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (-)-eseroline, (-)-(N1)-noreseroline and physovenol
Brzostowska M, He XS, Greig NH et al. Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (-)-eseroline, (-)-(N1)-noreseroline and physovenol. Med Chem Res 1992 2 : 238 246.
Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in transgenic model of Alzheimer disease
Olcese JM, Cao C, Moiri T et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in transgenic model of Alzheimer disease. J Pineal Res 2009 47 : 82 96.
